Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Minerva Neurosciences (NERV) Non-Current Deffered Revenue (2017 - 2020)

Minerva Neurosciences filings provide 2 years of Non-Current Deffered Revenue readings, the most recent being $41.2 million for Q1 2020.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $41.2 million in Q1 2020 year-over-year; TTM through Mar 2020 was $41.2 million, a N/A change, with the full-year FY2019 number at $41.2 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue hit $41.2 million in Q1 2020 for Minerva Neurosciences, roughly flat from $41.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $41.2 million in Q4 2019 to a low of $41.2 million in Q4 2019.